Contact this trialFirst, we need to learn more about you.
Cell Therapy
CYNK-001 for Respiratory Diseases
Recruiting1 awardPhase 1 & 2
Tacoma, Washington
This trial is to test a new immunotherapy for safety and efficacy on patients with moderate COVID-19. The immunotherapy contains NK cells from the placenta.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.